1 Porter JB, "Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone" 15 : 38-, 2013
2 Pennell DJ, "T2* magnetic resonance and myocardial iron in thalassemia" 1054 : 373-378, 2005
3 Voskaridou E, "Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies" 154 : 654-656, 2011
4 Chhim RF, "Recent new drug approvals, part 2: drugs undergoing active clinical studies in children" 18 : 14-38, 2013
5 Belhoul KM, "Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre" 33 : 18-21, 2013
6 Farmaki K, "Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major" 148 : 466-475, 2010
7 Kwiatkowski JL, "Management of transfusional iron overload -differential properties and efficacy of iron chelating agents" 2 : 135-149, 2011
8 Viprakasit V, "Deferiprone (GPO-L-ONE(Ⓡ)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand" 88 : 251-260, 2013
9 Balocco M, "Daily alternating deferasirox and deferiprone therapy for “hard-to-chelate” beta-thalassemia major patients" 85 : 460-461, 2010
10 Galanello R, "Combined iron chelation therapy" 1202 : 79-86, 2010